Markets:

Overview

News

Currencies

International

Treasuries

INmune Bio Inc. - Common stock (NQ:INMB)

2.175 -0.055 (-2.47%)

Streaming Delayed Price Updated: 2:57 PM EDT, Aug 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about INmune Bio Inc. - Common stock

< Previous 1 2 3 4 5 Next >

INmune Bio (INMB) Q2 2026 Earnings Call Transcript ↗

August 07, 2026

Ebstracel nears UK filing as XPro shows Alzheimer's biomarker progress.

Via The Motley Fool

Topics Earnings

INmune Bio Q2 Earnings Call Highlights ↗

August 06, 2026

INmune Bio (NASDAQ:INMB) outlined plans to file for conditional approval of its Ebstrocel cell therapy in the United Kingdom by the end of the third quarter or early in the fourth quarter of 2026,...

Via MarketBeat

Topics Earnings

INmune Bio (NASDAQ:INMB) Beats Q2 Loss Estimates but Shares Tumble on Business Update ↗

August 06, 2026

Via Chartmill

INmune Bio (INMB) Q4 2025 Earnings Transcript ↗

June 01, 2026

INmune Bio (INMB) Q4 2025 Earnings Transcript

Via The Motley Fool

INMUNE BIO INC (NASDAQ:INMB) Beats Q1 2026 EPS Estimates as Stock Shows Recent Momentum ↗

May 07, 2026

Via Chartmill

INMB Stock Rises Pre-Market – What Did The FDA Say About Its Alzheimer’s Trial? ↗

February 12, 2026

Via Stocktwits

INmune Bio (INMB) Q1 2026 Earnings Transcript ↗

May 08, 2026

INmune Bio (INMB) Q1 2026 Earnings Transcript

Via The Motley Fool

Topics Economy

INMUNE BIO INC (NASDAQ:INMB) Reports Narrower-Than-Expected Q3 2025 Loss ↗

October 30, 2025

INmune Bio (INMB) reported a narrower-than-expected Q3 2025 loss, sparking a positive after-hours market reaction for the clinical-stage biotech firm.

Via Chartmill

Earnings Scheduled For October 30, 2025 ↗

October 30, 2025

Via Benzinga

INmune Bio (INMB) Q2 Loss Widens 110% ↗

August 07, 2025

Via The Motley Fool

Topics Intellectual Property

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

August 07, 2025

Via Benzinga

Earnings Scheduled For August 7, 2025 ↗

August 07, 2025

Via Benzinga

What's going on in today's pre-market session ↗

August 04, 2025

As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.

Via Chartmill

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

August 04, 2025

Via Benzinga

Why Celcuity Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket ↗

July 28, 2025

Via Benzinga

INmune Bio Rebounds Sharply During After Hours Trading: What's Driving the Surge? ↗

July 28, 2025

Following the announcement of TNF inhibitor, INmune Bio Inc. stock surged by 24.72% in after-hours trading on Friday.

Via Benzinga

'Pharma Bro' Martin Shkreli Says 'Good Chance' Inmune Bio Stock Will Slip 90% On Monday ↗

July 04, 2025

Former hedge fund manager Martin Shkreli has issued a stark warning on the near-term trajectory of a biotech startup, just days after it witnessed a surge.

Via Benzinga

Which stocks have an unusual volume on Thursday? ↗

July 03, 2025

The trading volume of these stocks is deviating from the norm in today's session.

Via Chartmill

This Textron Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday ↗

July 01, 2025

Via Benzinga

Let's take a look at the stocks that are in motion in today's session. ↗

June 30, 2025

Stay up-to-date with the latest market trends one hour before the close of the markets on Monday. Explore the top gainers and losers during today's session in our detailed report.

Via Chartmill

Crude Oil Moves Lower; Joby Aviation Shares Surge ↗

June 30, 2025

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

June 30, 2025

Via Benzinga

Which stocks are moving on Monday? ↗

June 30, 2025

Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements.

Via Chartmill

Alzheimer's Setback Hits INmune Bio Stock, But FDA Hopes Remain ↗

June 30, 2025

INmune Bio's Alzheimer's drug XPro showed targeted benefits in patients with brain inflammation, but misses the main trial endpoint.

Via Benzinga

Dow Gains Over 100 Points; Chicago PMI Weakens In June ↗

June 30, 2025

Via Benzinga

Topics Stocks

Gapping stocks in Monday's session ↗

June 30, 2025

The session on Monday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.

Via Chartmill

INmune Bio Stock Slumps After Alzheimer’s Drug Falls Short In Mid-Stage Trial ↗

June 30, 2025

The primary endpoint of the study was not met in the intent-to-treat population, the company said.

Via Stocktwits

Get insights into the top gainers and losers of Monday's pre-market session. ↗

June 30, 2025

Discover the top movers in Monday's pre-market session and stay informed about market dynamics.

Via Chartmill

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

June 30, 2025

Via Benzinga

Why Venus Concept Shares Are Trading Higher By Over 32%; Here Are 20 Stocks Moving Premarket ↗

June 30, 2025

Via Benzinga

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

INmune Bio Inc. - Common stock (NQ:INMB)

Headline News about INmune Bio Inc. - Common stock

Starting at /week.